Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease
BMC Gastroenterology · 2024
DOI: 10.1186/s12876-024-03271-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Leichang Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China. Hauptthemen laut MEDLINE: Monocytes, Lipopolysaccharide Receptors, Inflammatory Bowel Diseases, HLA-DR Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD), a chronic inflammatory condition, is caused by several factors involving aberrant immune responses. Genetic factors are crucial in IBD occurrence. Mendelian randomization (MR) can offer a new perspective in understanding IBD’s genetic background.
Methods
Single nucleotide polymorphisms (SNPs) were considered instrumental variables (IVs). We analyzed the relationship between 731 immunophenotypes, 1,400 metabolite phenotypes, and IBD. The total effect was decomposed into indirect and direct effects, and the ratio of the indirect effect to the total effect was calculated.
Results
We identified the causal effects of HLA-DR-expressing CD14 + monocytes on IBD through MR analysis. The phenotype “HLA-DR expression on CD14 + monocytes” showed the strongest association among the selected 48 immune phenotypes. Chiro-inositol metabolites mediated the effect of CD14 + monocytes expressing HLA-DR on IBD. An increase in Chiro-inositol metabolites was associated with a reduced risk of IBD occurrence, accounting for 4.97%.
Conclusion
Our findings revealed a new pathway by which HLA-DR-expressing CD14 + monocytes indirectly reduced the risk of IBD occurrence by increasing the levels of Chiro-inositol metabolites. The results provided a new perspective on the immunoregulatory mechanisms underlying IBD, laying a theoretical foundation for developing new therapeutic targets in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China.
- Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330000, China.
- Affiliated Hospital of Jiangxi College of TCM, Nanchang, Jiangxi, 330000, China. 82598907@qq.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., Shen, P., Ge, W., Liao, W., Luo, Q., Li, C., Zhan, C., Yuan, X., Zhang, X., & Yan, X. (2024). Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03271-2
Vancouver
Zhang L, Shen P, Ge W, Liao W, Luo Q, Li C, et al. Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03271-2
BibTeX
@article{Zhang2024,
author = {Zhang, Leichang and Shen, Pan and Ge, Wei and Liao, Wu and Luo, Qinghua and Li, Chaofeng and Zhan, Chuanyu and Yuan, Xiao and Zhang, Xiaonan and Yan, Xiaojun},
title = {Mediating role of chiro-inositol metabolites on the effects of HLA-DR-expressing CD14 + monocytes in inflammatory bowel disease},
journal = {BMC Gastroenterology},
year = {2024},
doi = {10.1186/s12876-024-03271-2}
}
EUVIMED